---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000045"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T05:52:19.149307+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Salarius Pharma receives Nasdaq delisting notice for bid price non-compliance; merger with Decoy planned

## Summary
- Nasdaq notice on April 23, 2025 for failing minimum $1.00 bid price for 30 consecutive business days.
- Ineligible for compliance period due to prior reverse stock split; also non-compliant with $2.5M equity standard.
- Unless appeal by April 30, 2025, suspension and delisting scheduled for May 2, 2025; company intends to appeal.
- Plans to present merger with Decoy Therapeutics Inc. to regain compliance at Nasdaq Hearings Panel.

## SEC filing metadata
- accession: 0001615219-25-000045
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000045/0001615219-25-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000045/flks-20250423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000045
- JSON: https://secwatch.observer/filing/0001615219-25-000045.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.